Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Glycoconjugate Journal

Volumn 33, Issue 4, 2016, Pages 645-652

  Zhuang, Aowen ^a   Forbes, Josephine M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

AGE R1; AGEs; Diabetes; Diabetic kidney disease; Diabetic nephropathy; OST 48

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 1; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; AGER PROTEIN, HUMAN;

DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; GLYCATION END PRODUCTS, ADVANCED; HUMANS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS;

EID: 84981169465     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-016-9693-z     Document Type: Review

References (74)

1. Shaw J.E., Sicree R.A., Zimmet P.Z.: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14 (2010). doi:10.1016/j.diabres.2009.10.007
2. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., Lin J.K., Farzadfar F., Khang Y.H., Stevens G.A., Rao M., Ali M.K., Riley L.M., Robinson C.A., Ezzati M.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet (London, England). 378(9785), 31–40 (2011). doi:10.1016/s0140-6736(11)60679-x
3. Gerstein H.C., Pogue J., Mann J.F., Lonn E., Dagenais G.R., McQueen M., Yusuf S.: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 48(9), 1749–1755 (2005). doi:10.1007/s00125-005-1858-4
4. Fox C.S., Coady S., Sorlie P.D., D'Agostino Sr. R.B., Pencina M.J., Vasan R.S., Meigs J.B., Levy D., Savage P.J.: Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham heart study. Circulation. 115(12), 1544–1550 (2007). doi:10.1161/circulationaha.106.658948
5. Matsushita K., van der Velde M., Astor B.C., Woodward M., Levey A.S., de Jong P.E., Coresh J., Gansevoort R.T.: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (London, England). 375(9731), 2073–2081 (2010). doi:10.1016/s0140-6736(10)60674-5
6. Alsaad K.O., Herzenberg A.M.: Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J. Clin. Pathol. 60(1), 18–26 (2007). doi:10.1136/jcp.2005.035592
7. Kshirsagar A.V., Joy M.S., Hogan S.L., Falk R.J., Colindres R.E.: Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am. J. Kidney Dis.: the official journal of the National Kidney Foundation. 35(4), 695–707 (2000)
8. Zoungas S., de Galan B.E., Ninomiya T., Grobbee D., Hamet P., Heller S., MacMahon S., Marre M., Neal B., Patel A., Woodward M., Chalmers J., Cass A., Glasziou P., Harrap S., Lisheng L., Mancia G., Pillai A., Poulter N., Perkovic V., Travert F.: Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 32(11), 2068–2074 (2009). doi:10.2337/dc09-0959
9. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A.: 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008). doi:10.1056/NEJMoa0806470
10. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., Matthews D.R.: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359(15), 1565–1576 (2008). doi:10.1056/NEJMoa0806359
11. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861–869 (2001). doi:10.1056/NEJMoa011161
12. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358(23), 2433–2446 (2008). doi:10.1056/NEJMoa0708379
13. Roos J.F., Doust J., Tett S.E., Kirkpatrick C.M.: Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children–a meta-analysis. Clin. Biochem. 40(5–6), 383–391 (2007). doi:10.1016/j.clinbiochem.2006.10.026
14. Mathew T.H.: Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med. J. Aust. 183(3), 138–141 (2005)
15. Cooper B.A., Branley P., Bulfone L., Collins J.F., Craig J.C., Dempster J., Fraenkel M.B., Harris A., Harris D.C., Johnson D.W., Kesselhut J., Luxton G., Pilmore A., Pollock C.A., Tiller D.J.: The initiating dialysis early and late (IDEAL) study: study rationale and design. Perit. Dial. Int.: journal of the International Society for Peritoneal Dialysis. 24(2), 176–181 (2004)
16. Cooper B.A., Branley P., Bulfone L., Collins J.F., Craig J.C., Fraenkel M.B., Harris A., Johnson D.W., Kesselhut J., Li J.J., Luxton G., Pilmore A., Tiller D.J., Harris D.C., Pollock C.A.: A randomized, controlled trial of early versus late initiation of dialysis. N. Engl. J. Med. 363(7), 609–619 (2010). doi:10.1056/NEJMoa1000552
17. Tessari P., Garibotto G., Inchiostro S., Robaudo C., Saffioti S., Vettore M., Zanetti M., Russo R., Deferrari G.: Kidney, splanchnic, and leg protein turnover in humans. Insight from leucine and phenylalanine kinetics. J. Clin. Invest. 98(6), 1481–1492 (1996)
18. Goldspink D.F., Kelly F.J.: Protein turnover and growth in the whole body, liver and kidney of the rat from the foetus to senility. Biochem. J. 217(2), 507–516 (1984)
19. Forbes J.M., Cooper M.E.: Mechanisms of diabetic complications. Physiol. Rev. 93(1), 137–188 (2013). doi:10.1152/physrev.00045.2011
20. Dalla Vestra M., Masiero A., Roiter A.M., Saller A., Crepaldi G., Fioretto P.: Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 52(4), 1031–1035 (2003)
21. Steffes M.W., Schmidt D., McCrery R., Basgen J.M.: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 59(6), 2104–2113 (2001). doi:10.1046/j.1523-1755.2001.00725.x
22. Puelles V.G., Cullen-McEwen L.A., Taylor G.E., Li J., Hughson M.D., Kerr P.G., Hoy W.E.A.F., Bertram J.F.: Human podocyte depletion in association with older age and hypertension. Am. J. Physiol. Renal Physiol. (2016). doi:10.1152/ajprenal.00497.2015
23. Welsh G.I., Hale L.J., Eremina V., Jeansson M., Maezawa Y., Lennon R., Pons D.A., Owen R.J., Satchell S.C., Miles M.J., Caunt C.J., McArdle C.A., Pavenstadt H., Tavare J.M., Herzenberg A.M., Kahn C.R., Mathieson P.W., Quaggin S.E., Saleem M.A., Coward R.J.: Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 12(4), 329–340 (2010). doi:10.1016/j.cmet.2010.08.015
24. Herman-Edelstein M., Scherzer P., Tobar A., Levi M., Gafter U.: Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55(3), 561–572 (2014). doi:10.1194/jlr.P040501
25. Merscher-Gomez S., Guzman J., Pedigo C.E., Lehto M., Aguillon-Prada R., Mendez A., Lassenius M.I., Forsblom C., Yoo T., Villarreal R., Maiguel D., Johnson K., Goldberg R., Nair V., Randolph A., Kretzler M., Nelson R.G., Burke 3rd G.W., Groop P.H., Fornoni A.: Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes. 62(11), 3817–3827 (2013). doi:10.2337/db13-0399
26. Thameem F., Puppala S., Schneider J., Bhandari B., Arya R., Arar N.H., Vasylyeva T.L., Farook V.S., Fowler S., Almasy L., Blangero J., Duggirala R., Abboud H.E.: The Gly(972)Arg variant of human IRS1 gene is associated with variation in glomerular filtration rate likely through impaired insulin receptor signaling. Diabetes. 61(9), 2385–2393 (2012). doi:10.2337/db11-1078
27. Suzuki M., Isobe K., Fujii E., Yamazaki M., Takai Y., Soshin T., Akai S., Watanabe T., Kato A.: Cell proliferative activity in the kidney of young growing rat analyzed using flash and cumulative labeling with bromodeoxyuridine. J. Toxicol. Sci. 35(5), 631–637 (2010)
28. Ichikawa I., Ma J., Motojima M., Matsusaka T.: Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis. Curr. Opin. Nephrol. Hypertens. 14(3), 205–210 (2005)
29. Hara M., Yanagihara T., Kihara I.: Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron. 89(3), 342–347 (2001)
30. Kriz W., LeHir M.: Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int. 67(2), 404–419 (2005). doi:10.1111/j.1523-1755.2005.67097.x
31. Koschinsky T., He C.J., Mitsuhashi T., Bucala R., Liu C., Buenting C., Heitmann K., Vlassara H.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 94(12), 6474–6479 (1997)
32. He C., Sabol J., Mitsuhashi T., Vlassara H.: Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 48(6), 1308–1315 (1999)
33. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., Baynes J.W.: Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 43(5), 676–683 (1994)
34. Goldberg T., Cai W., Peppa M., Dardaine V., Baliga B.S., Uribarri J., Vlassara H.: Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc. 104(8), 1287–1291 (2004). doi:10.1016/j.jada.2004.05.214
35. Krishnamurti U., Rondeau E., Sraer J.D., Michael A.F., Tsilibary E.C.: Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J. Biol. Chem. 272(44), 27966–27970 (1997)
36. Charonis A.S., Reger L.A., Dege J.E., Kouzi-Koliakos K., Furcht L.T., Wohlhueter R.M., Tsilibary E.C.: Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes. 39(7), 807–814 (1990)
37. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., Sivitz W., Monnier V.M.: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 54(11), 3103–3111 (2005)
38. McIntyre N.J., Fluck R.J., McIntyre C.W., Taal M.W.: Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin. J. Am. Soc. Nephrol.: CJASN. 6(10), 2356–2363 (2011). doi:10.2215/cjn.02420311
39. Yubero-Serrano E.M., Woodward M., Poretsky L., Vlassara H., Striker G.E.: Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol.: CJASN. 10(5), 759–766 (2015). doi:10.2215/cjn.07750814
40. Lewis E.J., Greene T., Spitalewiz S., Blumenthal S., Berl T., Hunsicker L.G., Pohl M.A., Rohde R.D., Raz I., Yerushalmy Y., Yagil Y., Herskovits T., Atkins R.C., Reutens A.T., Packham D.K., Lewis J.B.: Pyridorin in type 2 diabetic nephropathy. J. Am. Soc. Nephrol.: JASN. 23(1), 131–136 (2012). doi:10.1681/asn.2011030272
41. Williams M.E., Bolton W.K., Khalifah R.G., Degenhardt T.P., Schotzinger R.J., McGill J.B.: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27(6), 605–614 (2007). doi:10.1159/000108104
42. Silberstein S., Kelleher D.J., Gilmore R.: The 48-kDa subunit of the mammalian oligosaccharyltransferase complex is homologous to the essential yeast protein WBP1. J. Biol. Chem. 267(33), 23658–23663 (1992)
43. Li Y.M., Mitsuhashi T., Wojciechowicz D., Shimizu N., Li J., Stitt A., He C., Banerjee D., Vlassara H.: Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80 K-H membrane proteins. Proc. Natl. Acad. Sci. U. S. A. 93(20), 11047–11052 (1996)
44. Yan K., Khoshnoodi J., Ruotsalainen V., Tryggvason K.: N-linked glycosylation is critical for the plasma membrane localization of nephrin. J. Am. Soc. Nephrol.: JASN. 13(5), 1385–1389 (2002)
45. Kestila M., Lenkkeri U., Mannikko M., Lamerdin J., McCready P., Putaala H., Ruotsalainen V., Morita T., Nissinen M., Herva R., Kashtan C.E., Peltonen L., Holmberg C., Olsen A., Tryggvason K.: Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome. Mol. Cell. 1(4), 575–582 (1998)
46. Fujii Y., Khoshnoodi J., Takenaka H., Hosoyamada M., Nakajo A., Bessho F., Kudo A., Takahashi S., Arimura Y., Yamada A., Nagasawa T., Ruotsalainen V., Tryggvason K., Lee A.S., Yan K.: The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int. 69(8), 1350–1359 (2006). doi:10.1038/sj.ki.5000317
47. Vlassara H., Brownlee M., Cerami A.: Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J. Exp. Med. 164(4), 1301–1309 (1986)
48. Lu C., He J.C., Cai W., Liu H., Zhu L., Vlassara H.: Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc. Natl. Acad. Sci. U. S. A. 101(32), 11767–11772 (2004). doi:10.1073/pnas.0401588101
49. He C.J., Koschinsky T., Buenting C., Vlassara H.: Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol. Med. (Cambridge, Mass.) 7(3), 159–168 (2001)
50. Coughlan M.T., Thallas-Bonke V., Pete J., Long D.M., Gasser A., Tong D.C., Arnstein M., Thorpe S.R., Cooper M.E., Forbes J.M.: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology. 148(2), 886–895 (2007). doi:10.1210/en.2006-1300
51. Cai W., He J.C., Zhu L., Lu C., Vlassara H.: Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc. Natl. Acad. Sci. U. S. A. 103(37), 13801–13806 (2006). doi:10.1073/pnas.0600362103
52. He C.J., Zheng F., Stitt A., Striker L., Hattori M., Vlassara H.: Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. Kidney Int. 58(5), 1931–1940 (2000). doi:10.1111/j.1523-1755.2000.00365.x
53. Vlassara H., Cai W., Goodman S., Pyzik R., Yong A., Chen X., Zhu L., Neade T., Beeri M., Silverman J.M., Ferrucci L., Tansman L., Striker G.E., Uribarri J.: Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 94(11), 4483–4491 (2009). doi:10.1210/jc.2009-0089
54. Sourris K.C., Harcourt B.E., Penfold S.A., Yap F.Y., Morley A.L., Morgan P.E., Davies M.J., Baker S.T., Jerums G., Forbes J.M.: Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp. Diabetes Res. 2010, 974681 (2010). doi:10.1155/2010/974681
55. Hoverfelt A., Sallinen R., Soderlund J.M., Forsblom C., Pettersson-Fernholm K., Parkkonen M., Groop P.H., Wessman M.: DDOST, PRKCSH and LGALS3, which encode AGE-receptors 1, 2 and 3, respectively, are not associated with diabetic nephropathy in type 1 diabetes. Diabetologia. 53(9), 1903–1907 (2010). doi:10.1007/s00125-010-1771-3
56. Lerouxel O., Mouille G., Andeme-Onzighi C., Bruyant M.P., Seveno M., Loutelier-Bourhis C., Driouich A., Hofte H., Lerouge P.: Mutants in DEFECTIVE GLYCOSYLATION, an Arabidopsis homolog of an oligosaccharyltransferase complex subunit, show protein underglycosylation and defects in cell differentiation and growth. Plant J.: for cell and molecular biology. 42(4), 455–468 (2005). doi:10.1111/j.1365-313X.2005.02392.x
57. Jones M.A., Ng B.G., Bhide S., Chin E., Rhodenizer D., He P., Losfeld M.E., He M., Raymond K., Berry G., H.H. F., M.R. H.: DDOST mutations identified by whole-exome sequencing are implicated in congenital disorders of glycosylation. Am. J. Hum. Genet. 90(2), 363–368 (2012). doi:10.1016/j.ajhg.2011.12.024
58. Dupre T., Vuillaumier-Barrot S., Chantret I., Sadou Yaye H., Le Bizec C., Afenjar A., Altuzarra C., Barnerias C., Burglen L., de Lonlay P., Feillet F., Napuri S., Seta N., Moore S.E.: Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital disorders of glycosylation type Ik): five new patients and seven novel mutations. J. Med. Genet. 47(11), 729–735 (2010). doi:10.1136/jmg.2009.072504
59. Cai W., He J.C., Zhu L., Chen X., Striker G.E., Vlassara H.: AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am. J.Physiol. Cell Physiol. 294(1), C145–C152 (2008). doi:10.1152/ajpcell.00350.2007
60. Cai W., Torreggiani M., Zhu L., Chen X., He J.C., Striker G.E., Vlassara H.: AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am. J. Physiol. Cell Physiol. 298(3), C624–C634 (2010). doi:10.1152/ajpcell.00463.2009
61. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280(5), E685–E694 (2001)
62. Napoli C., Martin-Padura I., de Nigris F., Giorgio M., Mansueto G., Somma P., Condorelli M., Sica G., De Rosa G., Pelicci P.: Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc. Natl. Acad. Sci. U. S. A. 100(4), 2112–2116 (2003). doi:10.1073/pnas.0336359100
63. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., Vlassara H.: Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150(2), 523–531 (1997)
64. Torreggiani M., Liu H., Wu J., Zheng F., Cai W., Striker G., Vlassara H.: Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am. J. Pathol. 175(4), 1722–1732 (2009). doi:10.2353/ajpath.2009.090138
65. Liang F., Kume S., Koya D.: SIRT1 and insulin resistance. Nat. Rev. Endocrinol. 5(7), 367–373 (2009). doi:10.1038/nrendo.2009.101
66. de Kreutzenberg S.V., Ceolotto G., Papparella I., Bortoluzzi A., Semplicini A., Dalla Man C., Cobelli C., Fadini G.P., Avogaro A.: Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes. 59(4), 1006–1015 (2010). doi:10.2337/db09-1187
67. Menghini R., Casagrande V., Cardellini M., Martelli E., Terrinoni A., Amati F., Vasa-Nicotera M., Ippoliti A., Novelli G., Melino G., Lauro R., Federici M.: MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 120(15), 1524–1532 (2009). doi:10.1161/circulationaha.109.864629
68. Vlassara H., Striker G.E.: AGE restriction in diabetes mellitus: a paradigm shift. Nature reviews. Endocrinology. 7(9), 526–539 (2011). doi:10.1038/nrendo.2011.74
69. Hasegawa K., Wakino S., Simic P., Sakamaki Y., Minakuchi H., Fujimura K., Hosoya K., Komatsu M., Kaneko Y., Kanda T., Kubota E., Tokuyama H., Hayashi K., Guarente L., Itoh H.: Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat. Med. 19(11), 1496–1504 (2013). doi:10.1038/nm.3363
70. Coughlan M.T., Yap F.Y., Tong D.C., Andrikopoulos S., Gasser A., Thallas-Bonke V., Webster D.E., Miyazaki J., Kay T.W., Slattery R.M., Kaye D.M., Drew B.G., Kingwell B.A., Fourlanos S., Groop P.H., Harrison L.C., Knip M., Forbes J.M.: Advanced glycation end products are direct modulators of beta-cell function. Diabetes. 60(10), 2523–2532 (2011). doi:10.2337/db10-1033
71. Cai W., Ramdas M., Zhu L., Chen X., Striker G.E., Vlassara H.: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 109(39), 15888–15893 (2012). doi:10.1073/pnas.1205847109
72. Forbes J.M., Cowan S.P., Andrikopoulos S., Morley A.L., Ward L.C., Walker K.Z., Cooper M.E., Coughlan M.T.: Glucose homeostasis can be differentially modulated by varying individual components of a western diet. J. Nutr. Biochem. 24(7), 1251–1257 (2013). doi:10.1016/j.jnutbio.2012.09.009
73. Yoshizaki T., Milne J.C., Imamura T., Schenk S., Sonoda N., Babendure J.L., Lu J.C., Smith J.J., Jirousek M.R., Olefsky J.M.: SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29(5), 1363–1374 (2009). doi:10.1128/mcb.00705-08
74. Uribarri J., Cai W., Ramdas M., Goodman S., Pyzik R., Chen X., Zhu L., Striker G.E., Vlassara H.: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 34(7), 1610–1616 (2011). doi:10.2337/dc11-0091